Company Overview and News

 
Automation And Staffing Agencies

2018-07-05 seekingalpha
We look at the impacts of automation and potential adoption timelines, all with a focus on the staffing industry.
FBR KELYA TBI KELYB IGPPF MAN FBRKF 0550

149
3 Industries Already Using Self-Driving Vehicles

2018-06-07 seekingalpha - 1
When researching potential investment opportunities, try not to get caught up in the hype of new technologies.
FBR RIO RIO CAT NVDA GOOG KMTUY FSUGY RTPPF FSUMF GOOGL RIO RTNTF FMG FBRKF DE

2
Fastbrick rebrands, lays out global plans

2018-06-07 businessnews.com.au - 1
Local tech company Fastbrick Robotics has rebranded as FBR, with the company aiming to broaden the use of its technology beyond bricklaying and construction.
FBR FBRKF

1
Fastbrick rebrand, assembly completion

2018-06-07 businessnews.com.au
Local tech company Fastbrick Robotics has rebranded as FBR, with the company aiming to broaden the use of its technology beyond bricklaying and construction.
FBR FBRKF

57
Cobots: The PCs Of The Robot Era

2018-05-15 seekingalpha - 1
One of the most promising new segments of the robotics markets is that of the collaborative robot (cobot).
FBR BCS SSNLF KUKAY HXSCF ADEP BC94 SMSN NC DDAIF OMRNY GS NXEPF TER HNWHF CTTAY FBRKF HXSCL SMSD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:FBR / FASTBRICK ROBOTICS LTD on message board site Silicon Investor.

Friedman, Billings u0026 Ramsey (FBR) Friedman, Billings u0026 Ramsey (FBR) Friedman, Billings u0026 Ramsey (FBR) FBR IPO ALERT THREAD (NYSE: FBG) FBR IPO ALERT THREAD (NYSE: FBG) FBR IPO ALERT THREAD (NYSE: FBG)
Asia Fiber (AFBR) Asia Fiber (AFBR) Asia Fiber (AFBR) FBR Asset Investment Corp (FB) FBR Asset Investment Corp (FB) FBR Asset Investment Corp (FB)
FBRR--FBR Capital---Shell Play w/ tremendous potential FBRR--FBR Capital---Shell Play w/ tremendous potential FBRR--FBR Capital---Shell Play w/ tremendous potential